CN107648247A - A kind of subcutaneous implantation sustained release preparation of efficiently preventing and treating animal acarid disease - Google Patents
A kind of subcutaneous implantation sustained release preparation of efficiently preventing and treating animal acarid disease Download PDFInfo
- Publication number
- CN107648247A CN107648247A CN201710805552.3A CN201710805552A CN107648247A CN 107648247 A CN107648247 A CN 107648247A CN 201710805552 A CN201710805552 A CN 201710805552A CN 107648247 A CN107648247 A CN 107648247A
- Authority
- CN
- China
- Prior art keywords
- acarid
- animal
- sustained release
- release preparation
- ovum
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1611—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Patent of the present invention is related to a kind of subcutaneous implantation sustained release preparation of efficiently preventing and treating animal acarid disease.To the effect that by the medicine ivermectin (doractin) of only mite killing worm adult,With that can kill or prevent acarid ovum,Young mite and medicine-etoxazole of deutonymph development,Both are mixed by appropriate ratio,Or animal subdermal implantation sustained release preparation is respectively prepared,In heeling-in and animal subcutaneus adipose tissue,Its sustained release in animal body can be kept,Its acarid to each stage in the history of life is set to have killing and arrested development effect,Ivermectin class medicine can be overcome to be only capable of killing adult and ovum can not being killed,Young mite,The drawbacks of fur-bearing animal acarid disease recurrent exerbation that deutonymph is brought,Can be with the treatment of long-acting slow-release and prevention animal acarid disease,Reduce the number of medication,Reach and save labour,Reduce raiser's risk that animal poisoning death and drug resistance acarid are faster formed caused by inappropriate medication,It is economical and practical,Duration of efficacy is grown,Desinsection is more thorough.
Description
Technical field
The invention belongs to fur and economic animal external parasite preventing and treating technical field, and in particular to a kind of efficiently preventing and treating
The exploitation of the subcutaneous implantation sustained release preparation of animal acarid disease is with making category.
Background technology
Fur economic animal acarid disease is to be parasitized as the acarid belonging to Sarcoptidae and itch mite section in the skin of fur-bearing animal
A kind of infectiousness ectoparasite disease triggered.Affected animal depilation, appetite can be caused to reduce or do not eat, become thin, anaemia, be immunized
Ability decline etc., has had a strong impact on the pelage quality of fur-bearing animal and its has grown and breed.As treatment is often made not in time
Into death, the strong influence economic benefit of raiser.It is used to treat fur-bearing animal acarid due to only on Vehicles Collected from Market
Medicine --- the oral formulations or ejection preparation of ivermectin class medicine (including doractin) of disease, their mite killing mechanism are
Consistent, and be only capable of killing adult and ovum, young mite, deutonymph can not being killed, therefore single administration can only kill part adult, itch mite
Life cycle it is longer (the itch mite history of life include ovum, young mite, deutonymph, into 4 stages of mite, be to need 10~13 into mite from egg development
My god), also adult can be hatched again by the ovum that does not kill, larva, nymph, thus need certain period of time continuously to use several times
Medicine, just it is avoided that the recurrent exerbation of fur-bearing animal acarid disease.Because raiser likes (convenience) is administered orally, but dosage and use
Improper and such medicine usage time of the administrated methods such as medicine time grasp is longer, causes current acarid to be produced to such medicine bright
The aobvious resistance to the action of a drug, or even it is in the presence of that dosage has reached toxic dose and has also been difficult to clean off acarid.Acarid disease turns into fur
The larger communicable disease of animal injury, huge economic loss is brought to raiser.
The content of the invention
For the above situation, the purpose of the present invention is to develop one kind by killing into mite with killing itch mite ovum, larva, nymph
Etoxazole be main component the preventing and treating acarid medicine that can be capable of long-acting slow-release under Animal Skin with heeling-in, the medicine combination can
The acarid of different developmental phases is killed simultaneously, and acarid in animal body, solution fur-bearing animal can be more effectively eradicated so as to reach
The problem of resistance to the action of a drug of acarid quickly produces, reduce the economic loss of raiser.
To achieve these goals, the technical solution adopted by the present invention is：It is a kind of efficiently to prevent and treat the subcutaneous of animal acarid disease
Embedding sustained release preparation, the several constituent mass numbers of component are as follows：Key component has 3 10 parts of ivermectin, or doractin 3
10 parts, etoxazole 3 10, and its auxiliary materials of slow-releasing granules is made includes：25 parts of medical silica-gel, 15 parts of adhesive.Magnesium stearate
0.1 1 parts etc..
Combine a preferred scheme, 1 part of ivermectin, 1 part of etoxazole, 1 1.5 parts of silica gel.
Combine two preferred schemes, 1 part of ivermectin, 1 part of etoxazole, 0.1 part of (xanthans+ethyl cellulose=1 of adhesive
：1) 0.1 part of magnesium stearate, it is pressed into heeling-in particle.
Three preferred schemes are combined, ivermectin is made respectively and is fabricated to slow-releasing granules respectively with etoxazole, the used time is according to mite
The index such as insect infection stage and gradient of infection and animal size determines heeling-in quantity and ratio.
Above scheme is both needed to the cylindrical particle into diameter 2.2mm, long 10mm or so by template construct, by burying during medication
Plant pin particle is embedded at animal subcutaneous fat.
The beneficial effects of the invention are as follows：
By the ivermectin for being only capable of killing acarid adult or doractin and acarid ovum, larva and the second of nymph can be killed
Mite azoles joint is fabricated to animal subdermal implantation sustained release preparation together to have work to the acarid in each stage in the history of life
With, can overcome ivermectin class medicine be only capable of killing adult and the shortcomings that ovum, young mite, deutonymph can not be killed, alone Yi Wei bacterium
Element must certain interval of time until ovum, larva and nymphal development into during adult again medication, it is necessary to which two can just have to medication three times
Effect kills acarid, the problem of avoiding recurrent exerbation.And two kinds of medicines are applied simultaneously, not only kill already present acarid adult but also
Ovum can effectively be killed simultaneously, block the husking of larva and nymph, and can kill constantly by ovum, larva and nymph hatch into
Worm, therefore a drug can obtain more preferable effect.
Due to by two types miticide use sustained-release implant taking design, respectively by adhesive or it is medical plus
Sustained release heeling-in particle is made in shaping silica gel, by particle heeling-in in the subcutaneous layer of fat of animal, makes both medicines in hypodermis
It middle diffusion, can effectively play a role up to 2~3 months, can be subtracted with the treatment of long-acting slow-release and prevention animal acarid disease
The number of few medication, reach and save labour, reduce raiser animal poisoning death and drug resistance mite caused by inappropriate medication
The risk that worm is faster formed, economical and practical, duration of efficacy length, desinsection are more thorough.Therefore insecticidal effect is significantly better than existing
All ivermectins or logical oral and injection type the miticidal effect to go out.
Embodiment
Embodiment 1：
1st, formula components
1 part of ivermectin (or doractin), 1 part of etoxazole, 2 2.5 parts of silica gel.
2nd, preparation method
By formula rate weigh silica gel A and two kinds of medicines be sufficiently mixed after add silica gel B (curing agent), smear into template,
Curing and demolding
3rd, application method
Detailed directions are that sustained-release implant taking is imbedded on the inside of animal groin or in the subcutaneus adipose tissue of neck relaxation,
It is recommended that loaded with sterilized tweezers gripping powder in heeling-in pin.Heeling-in quantity is according to the weight of animals, symptom weight and animal
Species and set, between general 2-8 grains.For example, fox be used for prevention can heeling-in 2-4 grains, for treat can heeling-in 3-8 grains.
Implement 2：
1st, formula components
1 part of ivermectin (or doractin), 1 part of etoxazole, 0.1 part of (xanthans+ethyl cellulose=1 of adhesive：1)
0.1 part of magnesium stearate
2nd, preparation method
Each component is weighed by formula rate, after mixing, heeling-in particle is made by granulator.Also can be by wet granulation system
Into particle.
3rd, application method
Detailed directions are that sustained-release implant taking is imbedded on the inside of animal groin or in the subcutaneus adipose tissue of neck relaxation,
It is recommended that loaded with sterilized tweezers gripping powder in heeling-in pin.Heeling-in quantity is according to the weight of animals, symptom weight and animal
Species and set, between general 1-4 grains.For example, fox be used for prevention can heeling-in 1-4 grains, for treat can heeling-in 2-5 grains.
Implement 3：
1st, formula components
1 part of ivermectin (or doractin), 1 part of etoxazole, 0.1 part of (PVP+ ethyl cellulose=1 of adhesive：1) it is hard
0.1 part of fatty acid magnesium
2nd, preparation method
Ivermectin (or doractin) and etoxazole are fabricated to slow-releasing granules respectively respectively, by the preparation side for implementing 2
Method
3rd, application method
With implement 2 application method, the used time according to the index such as mite infection stage and gradient of infection and animal size come
Determine heeling-in quantity and ratio.
Claims (3)
1. a kind of subcutaneous implantation sustained release preparation of efficiently preventing and treating animal acarid disease, is by that can kill the medicine of acarid adult such as Yi Wei
Rhzomorph (or doractin) makes cutification with that can suppress the drug combinations such as the medicine etoxazole of acarid ovum, larva and nymphal development
Lower sustained release implant preparation.This new formulation appropriately combines both, and is administered by the way of subdermal implantation, will be in the history of life
The acarid in each stage have effect, reach the effect of long-acting slow-release, reduce the number of medication, save it is artificial, it is economical and practical,
Duration of efficacy is grown, and desinsection is more thorough.
2. a kind of subcutaneous implantation sustained release preparation of efficiently preventing and treating animal acarid disease according to claim 1, by mite killing worm into
The ivermectin or doractin of worm are mixed and made into subdermal implantation with acting on the medicines such as acarid ovum, larva and nymph etoxazole and delayed
Release formulation.
3. a kind of subcutaneous implantation sustained release preparation of efficiently preventing and treating animal acarid disease according to claim 1, by mite killing worm into
The ivermectin or doractin of worm are fabricated to subdermal implantation respectively with acting on the medicines such as acarid ovum, larva and nymph etoxazole
Sustained release preparation, by being imbedded at animal hypodermis simultaneously, have the function that while kill different phase acarid.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710805552.3A CN107648247A (en) | 2017-09-08 | 2017-09-08 | A kind of subcutaneous implantation sustained release preparation of efficiently preventing and treating animal acarid disease |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710805552.3A CN107648247A (en) | 2017-09-08 | 2017-09-08 | A kind of subcutaneous implantation sustained release preparation of efficiently preventing and treating animal acarid disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN107648247A true CN107648247A (en) | 2018-02-02 |
Family
ID=61129422
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710805552.3A Pending CN107648247A (en) | 2017-09-08 | 2017-09-08 | A kind of subcutaneous implantation sustained release preparation of efficiently preventing and treating animal acarid disease |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107648247A (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104996438A (en) * | 2015-06-24 | 2015-10-28 | 西南大学柑桔研究所 | Miticidal composition |
-
2017
- 2017-09-08 CN CN201710805552.3A patent/CN107648247A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104996438A (en) * | 2015-06-24 | 2015-10-28 | 西南大学柑桔研究所 | Miticidal composition |
Non-Patent Citations (1)
| Title |
|---|
| 葛艳艳 等: "伊维菌素缓释皮下埋植剂对银黑狐疥螨病的防治", 《黑龙江畜牧兽医》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0990450B1 (en) | Pharmaceutical implants | |
| Dharani et al. | Traditional ethnoveterinary medicine | |
| CN106511267A (en) | Compound moxidectin drops as well as preparation method and application thereof | |
| Lok et al. | Activity of an injectable, sustained-release formulation of moxidectin administered prophylactically to mixed-breed dogs to prevent infection with Dirofilaria immitis | |
| DE69221454T2 (en) | Juvenile hormones systemically used against ectoparasites | |
| US6174866B1 (en) | Edible anti-parasite medication for domesticated animals | |
| CN107648247A (en) | A kind of subcutaneous implantation sustained release preparation of efficiently preventing and treating animal acarid disease | |
| CN110664806B (en) | Fipronil and methoprene dihydric alcohol plastid and preparation method and application thereof | |
| CN101966197A (en) | Composition for treating bovine severe compound parasitic infection and preparation method thereof | |
| CN109453146B (en) | Pathogenic microorganism resisting composition and preparation method and application thereof | |
| Nair | Ethno-Veterinary sciences and practices for reducing the use of antimicrobial and other veterinary drugs in veterinary practices | |
| CN106727552B (en) | Compound imidacloprid drops and its preparation method and application | |
| KR20100055025A (en) | Pharmaceutical composition of bee venom infusion preparation for bovine mastitis | |
| CN110772509A (en) | Imidacloprid and moxidectin diatomic alcohol plastid and preparation method and application thereof | |
| CN108743950A (en) | Insecticide and preparation method thereof | |
| AU2021102381A4 (en) | Method of Controlling Parasites | |
| RU2779877C1 (en) | Method for treatment of mastitis in cows during the dry period | |
| AU2017200250B2 (en) | A Tick Treatment | |
| CN112294831B (en) | Transdermal drop for expelling parasites on animals and preparation method thereof | |
| RU2564948C1 (en) | Method of treatment of endometritis in cows | |
| RU2199323C2 (en) | "denahyph" preparation for treating and preventing post partum endometritis in cows | |
| Sofyan et al. | SA-13 Scabiosis (Notoedres cati) in Cat | |
| Krasteva et al. | Comparing the anesthetic effect of lemongrass and lavender essential oil on bighead carp (Hypophthalmichthys nobilis, Richardson, 1845) stocking material. | |
| EP1177785A2 (en) | Growth promoting pharmaceutical implant | |
| CN105920091B (en) | Yak cattle hide fly repellent as well as preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20180202 |